Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) issued its earnings results on Thursday. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03, Briefing.com reports. The firm had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The company's revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.38) earnings per share.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock traded up $0.73 during trading on Friday, reaching $16.73. 2,418,301 shares of the company traded hands, compared to its average volume of 2,854,846. Intellia Therapeutics has a 1-year low of $13.95 and a 1-year high of $34.87. The firm has a market capitalization of $1.70 billion, a PE ratio of -3.08 and a beta of 1.81. The company has a 50 day moving average price of $19.17 and a 200-day moving average price of $22.22.

Insider Activity

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on NTLA. Chardan Capital decreased their target price on Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. StockNews.com raised Intellia Therapeutics to a "sell" rating in a research report on Friday. Citigroup dropped their price target on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Stifel Nicolaus lowered their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a research report on Wednesday, September 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $57.94.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.